DNA Nanorobots & AI could slash drug development times, Nanovery CEO says

DNA nanorobots—tiny, self-assembling machines capable of detecting diseases in blood samples within 2–4 hours

Syngene locks in Bristol Myers Squibb alliance through 2035

The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle

Rakuten Medical teams up with LOTTE Biologics to boost production of innovative cancer therapy

LOTTE Biologics will provide advanced manufacturing services for monoclonal antibody intermediates and their conjugates

Bayer acquires Attralus’ cardiac amyloidosis imaging agents

The deal to acquire AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) underscores Bayer’s commitment to expanding in molecular imaging and advancing precision cardiology

Pierre Fabre and Iktos team up to accelerate AI-driven cancer drug discovery

Iktos will deploy its AI-driven tools to accelerate the identification of optimized small-molecule candidates against a currently undisclosed oncology target

GRIN Therapeutics launches global Phase 3 trial for groundbreaking GRIN-NDD therapy

GRIN-NDD is one of the most complex neurodevelopmental disorders with limited treatment options today

Bayer acquires Attralus’ cutting-edge cardiac amyloidosis imaging agents

The acquisition of AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) positions Bayer at the forefront of cardiac amyloidosis diagnostics

NVIDIA & Eli Lilly launch $1 billion AI Lab to reinvent drug discovery

Teva and Royalty Pharma partner in $500 million deal to fast-track vitiligo treatment

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding

Complement Therapeutics’ gene therapy gains FDA fast-track for vision loss treatment

CTx001 targets Geographic Atrophy (GA) secondary to Age-related Macular Degeneration